Pulsenmore cites studies backing remote biophysical profile scans

Pulsenmore said two peer-reviewed studies in the U.S. and Israel support using its home ultrasound platform for remote biophysical profile assessments under clinician guidance. The findings could help the company expand from single-measure scans into software-driven prenatal care applications.

Why it matters: - Pulsenmore is trying to move its home ultrasound platform beyond basic measurements and into more advanced prenatal surveillance. - The new evidence could support broader clinical use, new software modules, and more recurring revenue from a SaaS model. - Biophysical Profile, or BPP, is already an established, reimbursed test used for pregnancies that need repeated fetal monitoring.

What happened: - Pulsenmore announced two independent peer-reviewed studies published in the International Journal of Gynecology & Obstetrics and AJOG MFM. - The studies were conducted at leading medical centers in the United States and Israel. - The research tested whether the ultrasound components of BPP could be performed with Pulsenmore’s home ultrasound platform under real-time clinician guidance. - The studies enrolled 55 pregnant women in total. - The work was led by Dr. Alex Peahl and colleagues at the University of Michigan, and by Prof. Eran Hadar and Dr. Anat Pardo at Rabin Medical Center in Israel.

The details: - Pulsenmore’s device lets pregnant women perform physician-prescribed ultrasound exams at home using a compact device connected to a smartphone. - Each exam is transmitted securely to a physician for remote review and clinical decision-making. - The platform has supported more than 250,000 home ultrasound examinations to date. - BPP is widely used to assess fetal well-being in pregnancies complicated by diabetes, fetal growth restriction, decreased fetal movements and post-term pregnancy. - About 10% of pregnancies require repeated antenatal fetal surveillance. - Both studies found high agreement between home ultrasound exams and conventional hospital-based assessments across fetal movement, fetal breathing, fetal tone, fetal presentation, fetal heart rate and amniotic fluid assessment. - The results support the feasibility of performing this complex fetal surveillance exam remotely under clinician guidance. - Prof. Eran Hadar and Dr. Anat Pardo said the studies showed, for the first time, that a complex ultrasound exam can be done remotely by a pregnant woman while maintaining high agreement with hospital-based exams. - Dr. Alex Peahl said the BPP4Me study is an important first step toward making antenatal testing available for all patients, including those facing the greatest barriers to care.

Between the lines: - The studies do more than validate one clinical workflow; they help Pulsenmore argue that its installed base can be upgraded with software-based applications instead of only new hardware use cases. - That matters because SaaS modules can expand the company’s addressable market while creating recurring revenue opportunities. - The push also fits a broader care model in which more pregnancy monitoring moves out of hospitals and into the home.

What's next: - Pulsenmore plans to keep expanding its platform through dedicated software-based clinical applications. - The company expects validated clinical applications to deepen value for healthcare providers and support long-term growth. - More evidence on remote prenatal assessments could help determine whether home-based BPP use scales beyond early studies.

The bottom line: - Pulsenmore now has peer-reviewed evidence that its home ultrasound platform can support remote BPP assessments, strengthening the case for a broader digital pregnancy-care product stack.